Christersson C, et al. - Researchers assessed the impact of apixaban vs warfarin on coagulation and primary hemostasis biomarkers in 4,850 atrial fibrillation (AF) patients in the biomarker substudy from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Vitamin K antagonist was used within 7 days before randomization in 60% patients. At randomization and after 2 months of study treatment, they assessed prothrombin fragment 1+2 (F1+2), D-dimer, soluble CD40 ligand and von Willebrand factor antigen. According to findings, a lower reduction in thrombin generation and fibrin turnover was observed in association with apixaban vs warfarin for stroke prevention in these patients. Apixaban’s superiority over warfarin in both stroke prevention and reducing bleeding risk could be a result of these effects.